Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance Watch: Sage Warns Of Job Cuts, Joins Peers Making Cash Last After Setbacks

Executive Summary

Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.

You may also be interested in...



Alvotech On The Financing Trail Once More Amid Teva Commitment

Alvotech has its eyes on raising more cash to fund operations and ease the pain of missing out on an FDA approval for its Teva-partnered Humira (adalimumab) biosimilar.

BMS Resets 2023 Guidance With Bigger Than Expected Drop In Revlimid Sales

Bristol saw a big jump in free Revlimid and Pomalyst provided through patient support programs. It does not expect the issue to persist in 2024, but now expects 2023 revenue to decline rather than grow.

Tarsus Targets Initial Small Segment Of Blepharitis Population With Xdemvy Approval

The company plans to focus on 7 million of the 25 million potentially addressable Demodex blepharitis patients at first, but even that could yield blockbuster sales over the next decade.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel